43.03
price down icon0.69%   -0.30
after-market After Hours: 43.10 0.07 +0.16%
loading
Avidity Biosciences Inc stock is traded at $43.03, with a volume of 434.99K. It is down -0.69% in the last 24 hours and down -3.46% over the past month. Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
See More
Previous Close:
$43.33
Open:
$43.33
24h Volume:
434.99K
Relative Volume:
0.37
Market Cap:
$5.13B
Revenue:
$10.60M
Net Income/Loss:
$-252.45M
P/E Ratio:
-13.88
EPS:
-3.1
Net Cash Flow:
$-158.91M
1W Performance:
-0.51%
1M Performance:
-3.46%
6M Performance:
+61.71%
1Y Performance:
+450.96%
1-Day Range:
Value
$42.22
$43.58
1-Week Range:
Value
$42.22
$45.98
52-Week Range:
Value
$6.79
$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name
Name
Avidity Biosciences Inc
Name
Phone
858-401-7900
Name
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
Employee
253
Name
Twitter
Name
Next Earnings Date
2024-12-07
Name
Latest SEC Filings
Name
RNA's Discussions on Twitter

Compare RNA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RNA
Avidity Biosciences Inc
43.03 5.13B 10.60M -252.45M -158.91M -2.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.13 120.56B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
750.22 82.44B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
616.55 36.87B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.07 32.64B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
118.39 28.38B 3.30B -501.07M 1.03B -2.1146

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-26-24 Initiated RBC Capital Mkts Outperform
Sep-24-24 Initiated Goldman Buy
Aug-28-24 Initiated Barclays Overweight
May-03-24 Initiated BofA Securities Buy
Mar-14-24 Initiated Cantor Fitzgerald Overweight
May-22-23 Upgrade Evercore ISI In-line → Outperform
Mar-31-23 Downgrade Evercore ISI Outperform → In-line
Jul-20-22 Initiated Chardan Capital Markets Buy
Jul-12-22 Initiated Raymond James Strong Buy
Sep-07-21 Initiated Evercore ISI Outperform
Jun-17-21 Initiated Needham Buy
Apr-26-21 Resumed Credit Suisse Outperform
Jul-07-20 Initiated Cowen Outperform
Jul-07-20 Initiated Credit Suisse Outperform
Jul-07-20 Initiated SVB Leerink Outperform
Jul-07-20 Initiated Wells Fargo Overweight
View All

Avidity Biosciences Inc Stock (RNA) Latest News

pulisher
Dec 01, 2024

Alethea Capital Management LLC Reduces Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Dec 01, 2024
pulisher
Nov 30, 2024

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - GuruFocus.com

Nov 30, 2024
pulisher
Nov 30, 2024

Avidity Biosciences Announces New Precision Cardiology Developme - GuruFocus.com

Nov 30, 2024
pulisher
Nov 28, 2024

Myotonic dystrophy pipeline shows momentum - The Pharma Letter

Nov 28, 2024
pulisher
Nov 28, 2024

Fmr LLC Has $773.86 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 28, 2024
pulisher
Nov 26, 2024

Dyne, Avidity initiated at outperform by RBC on DM1 drugs (NASDAQ:DYN) - Seeking Alpha

Nov 26, 2024
pulisher
Nov 26, 2024

Avidity Biosciences to Present at Evercore ISI HealthCONx Conference | RNA Stock News - StockTitan

Nov 26, 2024
pulisher
Nov 26, 2024

Royal Bank of Canada Begins Coverage on Avidity Biosciences (NASDAQ:RNA) - MarketBeat

Nov 26, 2024
pulisher
Nov 26, 2024

RBC Capital initiates Avidity Biosciences shares with Outperform rating By Investing.com - Investing.com Canada

Nov 26, 2024
pulisher
Nov 26, 2024

Intech Investment Management LLC Makes New $1.70 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 26, 2024
pulisher
Nov 26, 2024

Victory Capital Management Inc. Purchases 11,367 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 26, 2024
pulisher
Nov 25, 2024

RNA's SWOT analysis: promising pipeline drives biotech stock potential - Investing.com

Nov 25, 2024
pulisher
Nov 22, 2024

Connor Clark & Lunn Investment Management Ltd. Boosts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 22, 2024
pulisher
Nov 21, 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times

Nov 21, 2024
pulisher
Nov 20, 2024

Avidity Biosciences director Arthur Levin sells $139,972 in stock By Investing.com - Investing.com South Africa

Nov 20, 2024
pulisher
Nov 20, 2024

Avidity Biosciences director Arthur Levin sells $139,972 in stock - Investing.com India

Nov 20, 2024
pulisher
Nov 20, 2024

Avidity Biosciences' chief HR officer Teresa McCarthy sells $1.03m in stock - Investing.com Canada

Nov 20, 2024
pulisher
Nov 20, 2024

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Mutual of America Capital Management LLC Sells 19,252 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Research Analysts Set Expectations for RNA FY2024 Earnings - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

Los Angeles Capital Management LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

State of New Jersey Common Pension Fund D Buys Shares of 44,898 Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

12,319 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by Assetmark Inc. - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

Avidity Biosciences (NASDAQ:RNA) Shares Down 7.8%Time to Sell? - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

RA Capital Management's Strategic Acquisition in Avidity Bioscie - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Increases Stake in Avidity Biosciences Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Avidity Biosciences unveils new cardiology development candidates - BioWorld Online

Nov 14, 2024
pulisher
Nov 14, 2024

RNA Stock Hits Record High on Entering the Cardiac Disease Space - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

US Bancorp DE Cuts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat

Nov 14, 2024
pulisher
Nov 13, 2024

Avidity Biosciences stock soars to all-time high of $50.86 By Investing.com - Investing.com Canada

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 - Quantisnow

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences stock soars to all-time high of $50.86 - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences jumps 16%; reaches all-time high (RNA:NASDAQ) - Seeking Alpha

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences (NASDAQ:RNA) Reaches New 1-Year HighShould You Buy? - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Assessing Avidity Biosciences: Insights From 10 Financial Analysts - Benzinga

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire

Nov 13, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences (RNA) Stock Surges On Positive AOC 1020 Trial Results - Barchart

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences' SWOT analysis: RNA stock poised for growth in precision cardiology - Investing.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Unveils Advances in Cardiology Research - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences, Inc. Announces AOC 1072 and AOC 1086 as Initial Precision Cardiology Development Candidates and Shared First Look At Its Next-Generation Technology Innovations - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - Quantisnow

Nov 12, 2024
pulisher
Nov 09, 2024

Selling US$1.0m Of Avidity Biosciences Stock Rewarded Insiders - Simply Wall St

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Canada Finance

Nov 09, 2024
pulisher
Nov 09, 2024

431,210 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Fiera Capital Corp - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences CFO sells $4.8 million in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 09, 2024

Avidity Biosciences CFO sells $4.8 million in stock By Investing.com - Investing.com Canada

Nov 09, 2024

Avidity Biosciences Inc Stock (RNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.50
price up icon 1.61%
$74.59
price down icon 1.14%
$370.49
price down icon 2.02%
$43.06
price down icon 0.76%
$215.00
price up icon 4.29%
$118.39
price down icon 1.93%
Cap:     |  Volume (24h):